Enliven Therapeutics ELVN
NASDAQ ELVN
$41.81 +0.56 (+1.36%)
As of: Oct 21, 2026 · 3:59 PM EDT

Enliven Therapeutics (ELVN) EV to EBITDA (2022)

Updated

Enliven Therapeutics' EV to EBITDA came in at 86.43 for Q4 2022.

Analysis

Enliven Therapeutics (ELVN) EV to EBITDA (2022) Analysis & Trends

Over the trailing twelve months to Dec 31, 2022, Enliven Therapeutics reported EV to EBITDA of -863.92.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Enliven Therapeutics 2.77 Bn 482.20 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 86.43
API Access

Enliven Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=ELVN&period=max&api_key=YOUR_API_KEY